Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Steve Gallinger

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6998-9414; OpenAlex author ID A5016377624, A5110966875. Sources: ClinicalTrials.gov.

Their work

Papers
180 (first author 7, last author 22)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
3
Collaborators
455
Papers, trials and grants by year

2011: 3 papers · 2012: 11 papers · 2013: 8 papers · 2014: 8 papers · 2015: 15 papers · 2016: 10 papers · 2017: 7 papers, 1 trial · 2018: 8 papers · 2019: 10 papers · 2020: 19 papers · 2021: 22 papers · 2022: 13 papers · 2023: 12 papers · 2024: 8 papers · 2025: 14 papers · 2026: 12 papers

Papers 50 of 180

  1. AI-Based Segmentation Reduces the Retrospective Miss Rate of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s10278-025-01792-0↗
  2. Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, … Co-author DOI 10.1016/s1470-2045(25)00567-4↗
  3. Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models. Co-author DOI 10.1038/s41698-026-01479-x↗
  4. Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis. Co-author DOI 10.1093/jnci/djaf308↗
  5. Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-26-0793↗
  6. Deep Learning of Histopathology Predicts Outcomes After Surgery for Pancreatic Cancer. Co-author DOI 10.1200/cci-25-00268↗
  7. Multi-modal digital twin model outperforms conventional biomarker stratification in pancreatic cancer. Co-author DOI 10.3389/frai.2026.1873681↗
  8. Transcriptomic, Genomic, and Clinical Characterization of Morphological Classes in Localized and Metastatic Pancreatic Cancer Co-author DOI 10.64898/2026.04.07.717011↗
  9. Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals Co-author DOI 10.64898/2026.04.21.26351329↗
  10. Extra-lineage tissue programs define the transcription states of human pancreatic cancer Co-author DOI 10.64898/2026.04.29.721655↗
  11. Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer Co-author DOI 10.64898/2026.08.24.26360900↗
  12. Mutational signature landscape of pancreatic cancer genomes from nine countries Co-author DOI 10.64898/2026.10.21.26365999↗
  13. Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA. Co-author DOI 10.1002/1878-0261.13747↗
  14. GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial. Co-author DOI 10.1016/j.esmogo.2025.100138↗
  15. Multi-omics whole-genome characterization of the copy number landscape of metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2025.113176↗
  16. Allelic effects on KLHL17 expression underlie a pancreatic cancer genome-wide association signal at chr1p36.33. Co-author DOI 10.1038/s41467-025-59109-2↗
  17. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Co-author DOI 10.1038/s41467-025-60808-z↗
  18. The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. Co-author DOI 10.1038/s41698-025-00888-8↗
  19. Plasma cell-free DNA methylome as early detection and prognostic marker for pancreatic cancer Co-author DOI 10.1101/2025.05.29.25328569↗
  20. Integrated spatial proteomics of human PDAC uncovers an expanded tumour-immune-stroma spectrum with genomic associations Co-author DOI 10.1101/2025.08.15.670565↗
  21. The subclonal footprint of pervasive early dissemination in pancreatic cancer Co-author DOI 10.1101/2025.11.27.690823↗
  22. Multiplexed glycan immunofluorescence identification of pancreatic cancer cell subpopulations in both tumor and blood samples. Co-author DOI 10.1126/sciadv.adt0029↗
  23. MICAL2 Promotes Pancreatic Cancer Growth and Metastasis. Co-author DOI 10.1158/0008-5472.can-24-0744↗
  24. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Co-author DOI 10.1200/jco-25-00436↗
  25. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
  26. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  27. In vivo CRISPR screens reveal SCAF1 and USP15 as drivers of pancreatic cancer. Co-author DOI 10.1038/s41467-024-49450-3↗
  28. Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells. Co-author DOI 10.1038/s43018-024-00742-z↗
  29. INPP4B promotes PDAC aggressiveness via PIKfyve and TRPML-1-mediated lysosomal exocytosis. Co-author DOI 10.1083/jcb.202401012↗
  30. nSMase2-mediated exosome secretion shapes the tumor microenvironment to immunologically support pancreatic cancer Co-author DOI 10.1101/2024.09.23.614610↗
  31. Large Language Models for Automated Synoptic Reports and Resectability Categorization in Pancreatic Cancer. Co-author DOI 10.1148/radiol.233117↗
  32. Genome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-24-0096↗
  33. Molecular Characterization and Xenotransplantation of Pancreatic Cancer Using Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA). Co-author DOI 10.3390/cancers16152721↗
  34. Impact of an Inter-Professional Clinic on Pancreatic Cancer Outcomes: A Retrospective Cohort Study. Co-author DOI 10.3390/curroncol31050194↗
  35. Hourglass, a rapid analysis framework for heterogeneous bioimaging data, identifies sex disparity in IL-6/STAT3-associated immune phenotypes in pancreatic canc… Co-author DOI 10.1002/path.6199↗
  36. Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-023-02214-0↗
  37. RBFOX2 modulates a metastatic signature of alternative splicing in pancreatic cancer. Co-author DOI 10.1038/s41586-023-05820-3↗
  38. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325803↗
  39. Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. Co-author DOI 10.1136/jclinpath-2021-207781↗
  40. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Co-author DOI 10.1158/1055-9965.epi-23-0453↗
  41. hENT1 as a Predictive Biomarker in PDAC-Response. Co-author DOI 10.1158/1078-0432.ccr-23-0887↗
  42. Deciphering the Pathways to PARP Sensitivity in Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-23-2260↗
  43. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1158/1940-6207.capr-22-0529↗
  44. Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting. Co-author DOI 10.1158/2159-8290.cd-22-0412↗
  45. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of C… Co-author DOI 10.1200/jco.22.02770↗
  46. Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.3389/fgene.2023.1282824↗
  47. Pre-operative radiomics model for prognostication in resectable pancreatic adenocarcinoma with external validation. Co-author DOI 10.1007/s00330-021-08314-w↗
  48. Correlation of transcriptional subtypes with a validated CT radiomics score in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-022-09057-y↗
  49. The age-dependent association of risk factors with pancreatic cancer. Co-author DOI 10.1016/j.annonc.2022.03.276↗
  50. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗

Trials 1

  1. A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer Principal investigator NCT03257150↗

Closest collaborators

The 25 strongest of 455 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Grainne Mary O'Kane · 47 shared papers, 2018–2026 · strength 6.27
  2. Jennifer Jane Knox · 45 shared papers, 2018–2026 · strength 5.86
  3. Faiyaz Notta · 44 shared papers, 2016–2026 · strength 5.74
  4. Robert C. Grant · 42 shared papers, 2012–2026 · strength 5.31
  5. Ayelet Borgida · 39 shared papers, 2012–2026 · strength 3.12
  6. George Zogopoulos · 33 shared papers, 2012–2026 · strength 3.03
  7. Sandra Elisabeth Fischer · 26 shared papers, 2018–2026 · strength 3.02
  8. Erica S. Tsang · 12 shared papers, 2021–2026 · strength 2.11
  9. Daniel John Renouf · 16 shared papers, 2015–2026 · strength 1.84
  10. Barbara T. Grünwald · 13 shared papers, 2020–2026 · strength 1.79
  11. Spring Holter · 21 shared papers, 2012–2026 · strength 1.69
  12. Masoom A. Haider · 12 shared papers, 2012–2026 · strength 1.68
  13. David F. Schaeffer · 14 shared papers, 2015–2026 · strength 1.52
  14. Ashton Anthony Connor · 17 shared papers, 2015–2022 · strength 1.39
  15. Yifan Wang · 13 shared papers, 2019–2025 · strength 1.39
  16. Joanna M. Karasinska · 12 shared papers, 2019–2026 · strength 1.39
  17. Michelle Chan‐Seng‐Yue · 12 shared papers, 2016–2026 · strength 1.38
  18. David Arthur Tuveson · 10 shared papers, 2017–2026 · strength 1.27
  19. Gloria M. Petersen · 27 shared papers, 2011–2022 · strength 1.24
  20. James Thomas Topham · 11 shared papers, 2019–2026 · strength 1.23
  21. Malcolm J. Moore · 12 shared papers, 2012–2025 · strength 1.05
  22. Alison P. Klein · 14 shared papers, 2012–2022 · strength 0.99
  23. David Henault · 4 shared papers, 2024–2026 · strength 0.96
  24. Oliver F. Bathe · 7 shared papers, 2021–2025 · strength 0.92
  25. Eugenia Flores Figueroa · 6 shared papers, 2020–2026 · strength 0.92

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.